Mastectomy

SimBioSys Launches TumorSight Plan, A Pioneering Clinical Decision Support for Early-Stage Breast Cancer

Retrieved on: 
Tuesday, April 9, 2024
Technology, Biotechnology, Health, Consumer, Other Health, Radiology, Surgery, Artificial Intelligence, Oncology, Medical Devices, Software, General Health, Health Technology, Women, Breast cancer, MRI, Breast Cancer Care, Mastectomy, Science, Patient, Artificial intelligence, 3D, Cancer, Surgeon, Woman, Risk assessment, CMO, Simbiosys, FDA, Medicine, Medical imaging

Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.

Key Points: 
  • Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.
  • TumorSight Plan is powered by the FDA-cleared TumorSight Viz , an innovative 3D visualization solution to support the rapidly increasing use of MRI imaging in Breast Cancer.
  • SimBioSys’ TumorSight suite is a huge breakthrough in our capacity to utilize AI to calibrate a balance between decision standardization and individualized medicine.
  • TumorSight Plan gives the breast cancer surgeon a platform and opportunity to enable more analytical patient-centric decision making which should lead to higher percentage of women undergoing breast conservation surgery.”

USPS Honors Betty Ford

Retrieved on: 
Friday, April 5, 2024
Women's rights, Carnegie Hall, Equal Rights Amendment, Mastectomy, Newsroom, United, USPS, Republican Party, Disease, Betty Ford, Representative, Post, History, Female, Sale, Ford, Humour, Life, House, Collection, Betty Ford Center, Woman, Neck, News, Watergate scandal, Post office, White House Historical Association, Supreme court, Louisiana House of Representatives, The Postal Service, Breast cancer, Family, Hazelden Betty Ford Foundation, McReynolds, Divorce, Mail

RANCHO MIRAGE, Calif., April 5, 2024 /PRNewswire/ -- Today, the Postal Service issued a commemorative stamp celebrating the life of former First Lady Betty Ford on the campus of Eisenhower Health, adjacent to the Betty Ford Center in Rancho Mirage, CA. She was the wife of Gerald R. Ford, the 38th president, and widely admired for her support of women's rights and her candor about the serious health challenges she faced.

Key Points: 
  • RANCHO MIRAGE, Calif., April 5, 2024 /PRNewswire/ -- Today, the Postal Service issued a commemorative stamp celebrating the life of former First Lady Betty Ford on the campus of Eisenhower Health, adjacent to the Betty Ford Center in Rancho Mirage, CA.
  • Also attending were Susan Ford Bales, Betty Ford's daughter; Marty Massiello, CEO of Eisenhower Health; Dr. Joseph Lee, president and CEO of the Hazelden Betty Ford Foundation; and Tessa Voss, also of the foundation.
  • Betty Ford did that for both breast cancer and addiction — replacing shame and isolation with dignity, community and equitable care," Lee said.
  • In 1982, Ford and Leonard Firestone, a former ambassador and family friend, established the Betty Ford Center substance use disorder treatment center, which is now part of the nonprofit Hazelden Betty Ford Foundation.

Meijer Partners with Intimate Apparel Brand AnaOno to Bring Stylish and Comfortable Mastectomy Bras to its Tranquil & True Line

Retrieved on: 
Thursday, April 4, 2024
InStyle, Health, Culture, Mastectomy, Skin cancer, Woman, Disease, Partnership, Art, Survivor, Tranquillity, Breast cancer, Collection, Family, Birth control

GRAND RAPIDS, Mich., April 4, 2024 /PRNewswire/ -- Meijer customers across the Midwest can now find a new option in the intimates section: AnaOno x Tranquil & True, a collaboration between the leading mastectomy bra brand and the Meijer intimate apparel label.

Key Points: 
  • GRAND RAPIDS, Mich., April 4, 2024 /PRNewswire/ -- Meijer customers across the Midwest can now find a new option in the intimates section: AnaOno x Tranquil & True, a collaboration between the leading mastectomy bra brand and the Meijer intimate apparel label.
  • The collection features chest-inclusive bras specially designed for individuals who've undergone mastectomy, lumpectomy, reconstruction, or other breast surgeries.
  • Following bilateral mastectomies, breast reconstruction, and chemotherapy, Donofree struggled to find bras that fit her post-surgery body.
  • The AnaOno x Tranquil & True line is now available in more than 175 Meijer stores across six states.

INTERACT COALITION FORMED TO ADVANCE PATIENT ACCESS TO GENETIC TESTING FOR HEREDITARY CANCER RISK

Retrieved on: 
Wednesday, April 3, 2024
Ovarian cancer, Quest Diagnostics, Gene, Mutation, Genetic testing, Chemoprophylaxis, Incidence, Risk, Genetics, Education, SAN, Patient, Policy, Cancer, Hereditary nonpolyposis colorectal cancer, Salpingo-oophorectomy, Mastectomy, Breast cancer, Therapy, BRCA2, Physician, BRCA1, Cancer syndrome, Human, Vaccine

The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.

Key Points: 
  • The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.
  • With growing insight into the role of genetic testing in cancer risk management and treatment, the population of individuals who benefit from knowing their genetic mutation status continues to increase.
  • Hereditary cancer genetic testing has been shown to improve outcomes by identifying those most at risk and informing management strategies.
  • Among the challenges to broadening access to genetic testing for hereditary cancer risk is a time lag in updating guidelines and medical policies after the publication of new medical literature.

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Investment, FDA, Quality of life, Sensation, Growth, Q2, Mastectomy, Webcast, Nerve, Patient, Trauma, Internet, Video game

Fourth quarter revenue was $42.9 million, an 18.7% increase compared to the fourth quarter of 2022.

Key Points: 
  • Fourth quarter revenue was $42.9 million, an 18.7% increase compared to the fourth quarter of 2022.
  • The Company estimates that revenues from emergent trauma procedures represented approximately half of total revenues during the fourth quarter and grew mid-single digits versus the fourth quarter of 2022.
  • Gross margin was 78.7% for the fourth quarter compared to 83.0% in the fourth quarter of 2022.
  • Adjusted EBITDA was $0.6 million for the quarter, compared to an adjusted EBITDA loss of $0.7 million in the fourth quarter of 2022.

Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Research Examining the High Rates of Re-Operations Following Breast-Conserving Surgeries and the Associated Increased Healthcare Costs

Retrieved on: 
Tuesday, February 20, 2024
Woman, Perimeter, BCS, University, OTC, Surgeon, PINK, Surgical oncology, Risk, MD Anderson Cancer Center, Attention, PMID, Medicare, Mastectomy, Conversion, Patient, Research

The results of our study demonstrate that high reoperation rates after breast-conserving surgery persist and are correlated with elevated risks and adverse outcomes for patients.

Key Points: 
  • The results of our study demonstrate that high reoperation rates after breast-conserving surgery persist and are correlated with elevated risks and adverse outcomes for patients.
  • I believe that these data underscore the need for new approaches to address high reoperation rates, including better methods of margin assessment for surgeons."
  • Funding to support this research was provided, in part, by Perimeter Medical Imaging AI, Inc.
    1 Kim Y, Ganduglia-Cazaban C, Tamirisa N, Lucci A, Krause TM.
  • Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery.

Victoria’s Secret & Co. to Create New AI-Powered Shopping Experiences with Google Cloud

Retrieved on: 
Thursday, January 11, 2024
Cloud, Life, NRF, Partnership, PINK, Breast cancer, VS, Secrecy, Mastectomy, Marketing, Google Cloud, Google Workspace, Sales

Victoria’s Secret & Co. will leverage Google Cloud’s AI and generative AI technologies to create more personalized and inclusive online shopping experiences for its global customers.

Key Points: 
  • Victoria’s Secret & Co. will leverage Google Cloud’s AI and generative AI technologies to create more personalized and inclusive online shopping experiences for its global customers.
  • Through this partnership, VS&Co will also leverage Google Cloud’s AI technologies to improve customer and associate experiences and drive operational efficiencies within the business.
  • With Victoria’s Secret & Co.’s website now driving more than 500 million annual visits and growing, a key priority for the company is to leverage new technologies to create personalized customer experiences at scale.
  • Under the new, multi-year partnership, the brand will explore a new generative AI-powered conversational assistant, created with Google Cloud’s AI platform, Vertex AI.

Atossa Therapeutics Issues Letter to Shareholders

Retrieved on: 
Tuesday, January 9, 2024
Woman, Weill Cornell Medicine, Research, Breast cancer screening, Share repurchase, Exemestane, University, Neoadjuvant therapy, Prognosis, Cancer, Breast, Risk, Breast Cancer Research Foundation, Cell death, University of California, Mastectomy, Ductal carcinoma, Diagnosis, Nature Portfolio, Growth, Silicon, Quantum Leap, Therapy, Neoplasm, BCRF, Seminal vesicles, Breast cancer, Disease, Patient, Lymph, Apoptosis, Radiation, Letter, Recurrence, TNBC, Phenotype, DCIS, PKC, Partnership, Mayo Clinic, Plasma, Triple-negative breast cancer, AKT, Springer Nature, FDA, Biomarker, PCR, Phosphorylation, Medical imaging

SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:

Key Points: 
  • SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:
    2023 marked another year of significant progress for Atossa.
  • If you would like to learn more about the study, please visit www.atossatherapeutics.com to view a short video interview I conducted with Dr.
  • Adding to the issue is the fact that there are currently no approved treatments to reduce breast density.
  • On behalf of the board of directors, management, and employees of Atossa Therapeutics, we thank you for your investment and continued support of our Company.

Victoria's Secret & Co. to Create New AI-Powered Shopping Experiences with Google Cloud

Retrieved on: 
Thursday, January 11, 2024
Cloud, Life, NRF, Partnership, Secrecy, PINK, Breast cancer, VS, Adore Me, Vision, Mastectomy, Marketing, Google Cloud, Google Workspace, Victoria's Secret, Retail

REYNOLDSBURG, Ohio and SUNNYVALE, Calif., Jan. 11, 2024 /PRNewswire/ -- Ahead of NRF 2024, the retail industry's largest event, Victoria's Secret & Co. (VS&Co) and Google Cloud today announced a strategic, multi-year partnership. Victoria's Secret & Co. will leverage Google Cloud's AI and generative AI technologies to create more personalized and inclusive online shopping experiences for its global customers. Through this partnership, VS&Co will also leverage Google Cloud's AI technologies to improve customer and associate experiences and drive operational efficiencies within the business.

Key Points: 
  • Victoria's Secret & Co. will leverage Google Cloud's AI and generative AI technologies to create more personalized and inclusive online shopping experiences for its global customers.
  • Through this partnership, VS&Co will also leverage Google Cloud's AI technologies to improve customer and associate experiences and drive operational efficiencies within the business.
  • Victoria's Secret & Co. is actively exploring strategic ways to integrate Google Cloud's cutting-edge AI technologies to elevate its internal operations.
  • Victoria's Secret and Victoria's Secret PINK will also aim to enhance its website and mobile app by implementing Google Cloud's Vertex AI Search for retail technology.

SimBioSys Presents New Data for Breast Cancer Personalized Medicine Platforms at the 46th Annual San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, Biometrics, Surgery, Oncology, Other Science, Research, General Health, Hospitals, Genetics, Health Technology, Health Insurance, Science, Clinical Trials, Forecast, Neoplasm, Neoadjuvant therapy, Breast cancer, Surgeon, Perfusion, Patient, Tumor microenvironment, NAT, Artificial intelligence, BCS, Gene expression, Radiomics, Mastectomy, HER2, Cancer, PET, SOC, DCE, Medical imaging, Medical device, Dentistry, Health insurance, Simbiosys

SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and data science to redefine precision medicine for cancer with software tools, recently presented new data from its TumorSight and PhenoScope platforms at the 46th Annual San Antonio Breast Cancer Symposium (SABCS), held from December 5-9, 2023.

Key Points: 
  • SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and data science to redefine precision medicine for cancer with software tools, recently presented new data from its TumorSight and PhenoScope platforms at the 46th Annual San Antonio Breast Cancer Symposium (SABCS), held from December 5-9, 2023.
  • The results included collaborations with top cancer research institutions, multi-institutional analysis, enhanced visualization, and volumetric prediction capabilities to aid surgical planning.
  • (PO2-02-11) Radiomics and an Erosion Model to Predict Post-Neoadjuvant Therapy Tumor Characteristics for Personalized Breast Cancer Treatment.
  • Research Summary: Early breast cancer Patient Opinion Leaders (POLs) and surgeons were surveyed to assess TumorSight’s potential impact on shared decision making for breast cancer surgical options.